Developer docs
API playgroundTry for free, no card

Search company profiles

Aqsitania

Full company profile

uuid002m3vd

Namestring
Aqsitania
Legal namestring
Aqsitania SAS
Websiteurl
aqsitania.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Aqsitania SAS is a privately held French deep-tech company, founded in February 2014 and headquartered in Pessac near Bordeaux, that develops a proprietary signal-processing technology called AMASR (Analyse Morphologique Anharmonique des Signaux Respiratoires) for respiratory function assessment. The technology, originated by co-founder and President Patrick Hanusse after long theoretical research, is positioned as a break from conventional Fourier and wavelet approaches, enabling the extraction of fine-grained information from periodic respiratory waveforms to generate a unique Personal Respiratory Profile (PRP) for each patient. Its flagship product, Ventilom\u00e9trie, is a gentle, effort-free respiratory test applicable to all patient populations (children through elderly) that feeds the PRP and supports early detection of adverse events such as exacerbations, respiratory failure, and pulmonary edema.

The company commercializes this technology through three product lines: (1) T\u00e9l\u00e9surveillance, a home-based remote-monitoring service for chronic respiratory patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants); (2) Ventilosmart, a consumer mobile application extending the technology to professional athletes and the general public for respiratory self-evaluation; and (3) bespoke AMAS signal-analysis services for adjacent physiological signals (cardiac, cardio-respiratory, sleep) for industrial and academic clients. Revenue is generated through recurring telemonitoring engagements with French university hospitals (CHU) and pharmaceutical partner Chiesi (via the WeStart program co-run with IBM), supplemented by professional-services revenue from custom projects.

Aqsitania's commercial footprint remains small (1-10 employees, no disclosed VC funding, primary market France with nascent Spanish presence), and customer engagement is dominated by long-standing clinical research collaborations with major French university hospitals including AP-HP Piti\u00e9-Salp\u00e4tri\u00e8re, CHU de Bordeaux, Grenoble, Lyon, and Rouen, alongside academic partnerships with Universit\u00e9 Paris-Sorbonne, Bordeaux, and Grenoble-Alpes. Go-to-market relies on peer-reviewed clinical validation presented at the European Respiratory Society congresses, healthcare trade shows (HIT Paris, MWC/4YFN Barcelona, ConHIT Berlin), and a network of 2023 ecosystem memberships (FrenchTech, Les DeepTech, Barcelona Health Hub, Allis-NA). The company was recognized with the Concours national d'aide \u00e0 la cr\u00e9ation d'entreprises innovantes and the Troph\u00e9e de la e-sant\u00e9 awards.

Short descriptiontext

Aqsitania is a French deep-tech company that commercializes its proprietary AMASR respiratory signal-processing technology through Ventilom\u00e9trie telemonitoring for chronic respiratory patients, the Ventilosmart consumer app, and bespoke signal-analysis services for hospital, pharmaceutical, and sports clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPessac, France
HQ citystring
Pessac
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory telemonitoring, signal analysis, ventilometry, chronic disease monitoring, respiratory diagnostics
Industry4 codes
PRIMARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAKANAA
General Pulmonology Practice
SECONDARYHLALAGAK
Allergy & Immunology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Misc Health & Allied Services, Nec8090
Product category
Remote Patient Monitoring
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Telemonitoring/Telesurveillance Services
TypeSubscription Recurring
Description

Recurring telemonitoring services for chronic respiratory patients enabling remote health monitoring from home, potentially subscription or service-based model.

aqsitania.com
2Custom Signal Analysis Projects
TypeProfessional Services
Description

Bespoke signal analysis project services for healthcare and other sectors using their proprietary AMAS technology, including cardiac, cardio-respiratory, and sleep signals.

aqsitania.com
3Sports Respiratory Evaluation
TypeProfessional Services
Description

Individual respiratory evaluation services for athletes and sports professionals, including personal respiratory profile establishment and long-term monitoring.

aqsitania.com
4Signal Analysis Service
TypeProfessional Services
Description

Analysis services helping clients improve time and quality of results in signal analysis studies using their unique AMAS technology.

aqsitania.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aqsitania provides respiratory telemonitoring and diagnostics for chronically ill patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants) and professional athletes, powered by its proprietary AMASR signal processing technology. The company's core products include Ventilométrie (effort-free respiratory function assessment), the Personal Respiratory Profile (PRP), home-based telemonitoring services, the Ventilosmart consumer mobile application, and bespoke signal analysis projects. The technology enables new biomarkers and early detection of respiratory deterioration that traditional signal processing methods cannot identify.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Clinical validation at major European respiratory congresses including ERS 2014 (Munich), ERS 2019 (Madrid), ERS 2022 (Barcelona) with peer-reviewed presentations
Product overview1 text field

Aqsitania offers a unified product portfolio centered on its proprietary AMASR (Analyse Morphologique Anharmonique des Signaux Respiratoires) signal analysis technology. The core offering is Ventilométrie, a gentle respiratory function evaluation method that generates each patient's unique Personal Respiratory Profile (PRP). This feeds into two main service lines: (1) Télésurveillance — remote monitoring of chronic respiratory patients (asthma, COPD, cystic fibrosis, lung transplants) from home; and (2) Sport et auto-évaluation respiratoire — respiratory self-evaluation for athletes. The Ventilosmart sub-brand delivers the Ventilometry capability as a consumer-facing mobile application. Aqsitania also offers bespoke signal analysis and project management services for other physiological signal types (cardiac, sleep, etc.) using the same AMAS technology platform.

Product and service7 records
1Ventilométrie (Ventilometry)
CategoryRespiratory diagnostic method
Description

Flagship diagnostic and monitoring method based on the AMASR technology. It enables fine-grained evaluation of respiratory function through the analysis of resting breathing patterns, requiring no patient effort and applicable to all patients from children to the elderly. Used for diagnosis, remote monitoring, and respiratory performance follow-up.

2Profil Respiratoire Personnel (PRP) - Personal Respiratory Profile
CategoryPersonalized respiratory biomarker
Description

A unique 'respiratory identity card' for each patient, defined through AMASR analysis during calm breathing. The PRP enables detection of deviations or anomalies in respiratory markers, allowing anticipation of adverse events (exacerbations, respiratory failure, pulmonary edema) and evaluation of treatment effects.

3Ventilosmart
CategoryConsumer mobile application
Description

Individual consumer-facing mobile application version of Ventilometry, making respiratory function monitoring accessible to the general public and professional athletes in addition to hospital (CHU) usage.

4Télésurveillance des affections respiratoires chroniques (Chronic respiratory telemonitoring)
CategoryRemote patient monitoring service
Description

Tele-monitoring service for chronic respiratory patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants) enabling remote monitoring and patient safety at home using connected autonomous devices or mobile applications, aimed at reducing hospital readmissions.

5Sport et auto-évaluation respiratoire (Sports respiratory self-evaluation)
CategorySports performance service
Description

Respiratory self-evaluation service for athletes based on simple measurements of normal breathing taken at rest or during an exercise protocol, enabling personalized respiratory monitoring, training personalization, and performance optimization.

6Analyse de Signaux (AMAS) - Custom signal analysis
CategorySignal analysis service
Description

Custom signal analysis services for physiological signals (respiratory, cardiac, cardio-respiratory, sleep) using proprietary AMAS technology, offering clients a new vision of information carried by their signals with significantly improved analysis quality compared to traditional tools (Fourier, wavelets).

7Construction et Gestion de Projets (Project building and management)
CategoryProject management service
Description

Collaborative project building and management service for custom signal analysis projects, implemented according to industry best practices within Aqsitania's scope of intervention.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Les DeepTech
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2023-11-01
Description

Aqsitania entered the 'Les DeepTech' community of disruptive startups in November 2023, recognizing its breakthrough technology and innovation in deep tech.

aqsitania.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2023-06-01
Description

Aqsitania became a member of Barcelona Health Hub in June 2023, joining a digital health ecosystem focused on innovation in healthcare technology and international networking.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2023-03-01
Description

Aqsitania became a member of the FrenchTech community in March 2023, gaining access to the French startup ecosystem support network and national visibility for innovative technology companies.

4WeStart (Chiesi and IBM)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-01
Description

Aqsitania entered the WeStart program organized by pharmaceutical company Chiesi and technology company IBM, aimed at promoting and industrializing its innovation for chronic respiratory disease management. This strategic partnership provides access to pharmaceutical industry expertise and technological resources.

aqsitania.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing clinical research partnership with Assistance Publique - Hôpitaux de Paris at La Pitié-Salpêtrière hospital for respiratory function characterization studies and clinical validation.

6CHU de Bordeaux
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration with Centre Hospitalier Universitaire de Bordeaux for respiratory signal analysis research and clinical validation.

aqsitania.com
7CHU de Grenoble
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research partnership with Centre Hospitalier Universitaire de Grenoble for respiratory function studies.

aqsitania.com
8CHU de Lyon
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration with Centre Hospitalier Universitaire de Lyon for respiratory signal analysis research.

aqsitania.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hospital partnership with Centre Hospitalier Universitaire de Rouen for clinical research collaboration.

10Université Paris-Sorbonne
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with Sorbonne University for collaborative respiratory function research alongside APHP clinicians.

aqsitania.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaboration with University of Bordeaux Hospital for clinical research in respiratory medicine.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with Université Grenoble-Alpes (formerly Grenoble-Alphes) for respiratory research collaboration.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Alliance Innovation Santé member organization focused on health innovation in Nouvelle-Aquitaine region.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

TidalSense is a UK respiratory diagnostics and telehealth company using novel sensor and signal-analysis approaches (e.g., N-Tidal capnography) to diagnose and monitor chronic respiratory conditions — directly comparable in mission, technology approach, and clinical customer base to Aqsitania.

TypeBroad incumbent
Description

ResMed is a global leader in connected sleep and respiratory care devices (CPAP, ventilation) and now owns Propeller Health; it competes in the same chronic-respiratory monitoring category as Aqsitania but operates at vastly greater scale and with established payer/provider integration.

TypeDirect peer
Description

NuvoAir is a digital-health company offering remote respiratory monitoring, virtual pulmonary care, and connected spirometry for patients with asthma, COPD, and cystic fibrosis — directly mirroring Aqsitania's chronic-respiratory telemonitoring use cases and target customers (patients, providers, payers).

TypeEmerging player
Description

Bodyport builds a connected cardiovascular-monitoring scale that captures cardiac and respiratory signals for heart-failure and chronic-disease management, partially overlapping with Aqsitania's cardiac and cardio-respiratory signal-analysis service line.

TypeDirect peer
Description

Propeller Health (acquired by ResMed) provides connected inhaler sensors and digital respiratory health programs for asthma and COPD — a direct functional parallel to Aqsitania's Telesurveillance service for the same patient populations.

6VitalConnect
TypeEmerging player
Description

VitalConnect provides wearable biosensor patches and remote patient monitoring for cardiac and respiratory vital signs, an emerging-player analog to Aqsitania's connected-device-plus-software respiratory telemonitoring stack.

TypeBroad incumbent
Description

Philips is a major incumbent in hospital and home respiratory monitoring, ventilation, and telehealth; it competes broadly with Aqsitania across both hospital diagnostics (spirometry/ventilometry) and home telemonitoring, though not as a focused deep-tech niche player.

TypeDirect peer
Description

Adherium designs connected inhaler sensors and remote respiratory monitoring platforms for asthma and COPD adherence, overlapping directly with Aqsitania's AMASR-based chronic-respiratory telemonitoring offering and target user base.

9Spire Health
TypeEmerging player
Description

Spire Health offers wearable continuous respiratory and sleep monitoring for chronic-condition management, overlapping with Aqsitania's home-based telemonitoring and chronic-respiratory signal-analysis capabilities.

TypeDirect peer
Description

ResApp developed smartphone-based respiratory-diagnostic algorithms (e.g., cough/sound analysis) for conditions such as COPD, asthma, and pneumonia — directly comparable to Aqsitania's software-based, non-effort-dependent respiratory assessment approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aqsitania

Remote Patient Monitoringaqsitania.com

Aqsitania is a French deep-tech company that commercializes its proprietary AMASR respiratory signal-processing technology through Ventilom\u00e9trie telemonitoring for chronic respiratory patients, the Ventilosmart consumer app, and bespoke signal-analysis services for hospital, pharmaceutical, and sports clients.

What Aqsitania does

Aqsitania SAS is a privately held French deep-tech company, founded in February 2014 and headquartered in Pessac near Bordeaux, that develops a proprietary signal-processing technology called AMASR (Analyse Morphologique Anharmonique des Signaux Respiratoires) for respiratory function assessment. The technology, originated by co-founder and President Patrick Hanusse after long theoretical research, is positioned as a break from conventional Fourier and wavelet approaches, enabling the extraction of fine-grained information from periodic respiratory waveforms to generate a unique Personal Respiratory Profile (PRP) for each patient. Its flagship product, Ventilom\u00e9trie, is a gentle, effort-free respiratory test applicable to all patient populations (children through elderly) that feeds the PRP and supports early detection of adverse events such as exacerbations, respiratory failure, and pulmonary edema.

The company commercializes this technology through three product lines: (1) T\u00e9l\u00e9surveillance, a home-based remote-monitoring service for chronic respiratory patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants); (2) Ventilosmart, a consumer mobile application extending the technology to professional athletes and the general public for respiratory self-evaluation; and (3) bespoke AMAS signal-analysis services for adjacent physiological signals (cardiac, cardio-respiratory, sleep) for industrial and academic clients. Revenue is generated through recurring telemonitoring engagements with French university hospitals (CHU) and pharmaceutical partner Chiesi (via the WeStart program co-run with IBM), supplemented by professional-services revenue from custom projects.

Aqsitania's commercial footprint remains small (1-10 employees, no disclosed VC funding, primary market France with nascent Spanish presence), and customer engagement is dominated by long-standing clinical research collaborations with major French university hospitals including AP-HP Piti\u00e9-Salp\u00e4tri\u00e8re, CHU de Bordeaux, Grenoble, Lyon, and Rouen, alongside academic partnerships with Universit\u00e9 Paris-Sorbonne, Bordeaux, and Grenoble-Alpes. Go-to-market relies on peer-reviewed clinical validation presented at the European Respiratory Society congresses, healthcare trade shows (HIT Paris, MWC/4YFN Barcelona, ConHIT Berlin), and a network of 2023 ecosystem memberships (FrenchTech, Les DeepTech, Barcelona Health Hub, Allis-NA). The company was recognized with the Concours national d'aide \u00e0 la cr\u00e9ation d'entreprises innovantes and the Troph\u00e9e de la e-sant\u00e9 awards.

Aqsitania firmographics

Firmographics
Name
Aqsitania
Legal name
Aqsitania SAS
Website
https://aqsitania.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Aqsitania is a French deep-tech company that commercializes its proprietary AMASR respiratory signal-processing technology through Ventilom\u00e9trie telemonitoring for chronic respiratory patients, the Ventilosmart consumer app, and bespoke signal-analysis services for hospital, pharmaceutical, and sports clients.
Ownership category
akta.pro rank

Aqsitania industry classification

Industry
Product category
Remote Patient Monitoring
NAICS
Medical and Diagnostic Laboratories (62151), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Scientific and Technical Consulting Services (54169)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLALAGAF
Pulmonology & Sleep Medicine Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAKANAA
General Pulmonology Practice
SECONDARYHLALAGAK
Allergy & Immunology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Respiratory telemonitoring
  • Signal analysis
  • Ventilometry
  • Chronic disease monitoring
  • Respiratory diagnostics

Where Aqsitania is headquartered

Location

Headquarters

HQ city
Pessac
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Aqsitania business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Telemonitoring/Telesurveillance Services: Recurring telemonitoring services for chronic respiratory patients enabling remote health monitoring from home, potentially subscription or service-based model.
  2. Custom Signal Analysis Projects: Bespoke signal analysis project services for healthcare and other sectors using their proprietary AMAS technology, including cardiac, cardio-respiratory, and sleep signals.
  3. Sports Respiratory Evaluation: Individual respiratory evaluation services for athletes and sports professionals, including personal respiratory profile establishment and long-term monitoring.
  4. Signal Analysis Service: Analysis services helping clients improve time and quality of results in signal analysis studies using their unique AMAS technology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Aqsitania product offering

Product offering

Core offering

Aqsitania provides respiratory telemonitoring and diagnostics for chronically ill patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants) and professional athletes, powered by its proprietary AMASR signal processing technology. The company's core products include Ventilométrie (effort-free respiratory function assessment), the Personal Respiratory Profile (PRP), home-based telemonitoring services, the Ventilosmart consumer mobile application, and bespoke signal analysis projects. The technology enables new biomarkers and early detection of respiratory deterioration that traditional signal processing methods cannot identify.

Product overview

Aqsitania offers a unified product portfolio centered on its proprietary AMASR (Analyse Morphologique Anharmonique des Signaux Respiratoires) signal analysis technology. The core offering is Ventilométrie, a gentle respiratory function evaluation method that generates each patient's unique Personal Respiratory Profile (PRP). This feeds into two main service lines: (1) Télésurveillance — remote monitoring of chronic respiratory patients (asthma, COPD, cystic fibrosis, lung transplants) from home; and (2) Sport et auto-évaluation respiratoire — respiratory self-evaluation for athletes. The Ventilosmart sub-brand delivers the Ventilometry capability as a consumer-facing mobile application. Aqsitania also offers bespoke signal analysis and project management services for other physiological signal types (cardiac, sleep, etc.) using the same AMAS technology platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ventilométrie (Ventilometry) Flagship diagnostic and monitoring method based on the AMASR technology. It enables fine-grained evaluation of respiratory function through the analysis of resting breathing patterns, requiring no patient effort and applicable to all patients from children to the elderly. Used for diagnosis, remote monitoring, and respiratory performance follow-up.
  • Profil Respiratoire Personnel (PRP) - Personal Respiratory Profile A unique 'respiratory identity card' for each patient, defined through AMASR analysis during calm breathing. The PRP enables detection of deviations or anomalies in respiratory markers, allowing anticipation of adverse events (exacerbations, respiratory failure, pulmonary edema) and evaluation of treatment effects.
  • Ventilosmart Individual consumer-facing mobile application version of Ventilometry, making respiratory function monitoring accessible to the general public and professional athletes in addition to hospital (CHU) usage.
  • Télésurveillance des affections respiratoires chroniques (Chronic respiratory telemonitoring) Tele-monitoring service for chronic respiratory patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants) enabling remote monitoring and patient safety at home using connected autonomous devices or mobile applications, aimed at reducing hospital readmissions.
  • Sport et auto-évaluation respiratoire (Sports respiratory self-evaluation) Respiratory self-evaluation service for athletes based on simple measurements of normal breathing taken at rest or during an exercise protocol, enabling personalized respiratory monitoring, training personalization, and performance optimization.
  • Analyse de Signaux (AMAS) - Custom signal analysis Custom signal analysis services for physiological signals (respiratory, cardiac, cardio-respiratory, sleep) using proprietary AMAS technology, offering clients a new vision of information carried by their signals with significantly improved analysis quality compared to traditional tools (Fourier, wavelets).
  • Construction et Gestion de Projets (Project building and management) Collaborative project building and management service for custom signal analysis projects, implemented according to industry best practices within Aqsitania's scope of intervention.

Quantifiable outcome

  • Clinical validation at major European respiratory congresses including ERS 2014 (Munich), ERS 2019 (Madrid), ERS 2022 (Barcelona) with peer-reviewed presentations

Companies that use Aqsitania

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Aqsitania technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Aqsitania partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Les DeepTechcoreGTM or Marketing Partner · 1 November 2023Aqsitania entered the 'Les DeepTech' community of disruptive startups in November 2023, recognizing its breakthrough technology and innovation in deep tech.
  • Barcelona Health HubcoreGTM or Marketing Partner · 1 June 2023Aqsitania became a member of Barcelona Health Hub in June 2023, joining a digital health ecosystem focused on innovation in healthcare technology and international networking.
  • FrenchTechcoreGTM or Marketing Partner · 1 March 2023Aqsitania became a member of the FrenchTech community in March 2023, gaining access to the French startup ecosystem support network and national visibility for innovative technology companies.
  • WeStart (Chiesi and IBM)coreStrategic or Co-development Partner · 1 February 2020Aqsitania entered the WeStart program organized by pharmaceutical company Chiesi and technology company IBM, aimed at promoting and industrializing its innovation for chronic respiratory disease management. This strategic partnership provides access to pharmaceutical industry expertise and technological resources.
  • AP-HP Hôpital de la Pitié-SalpêtrièrecoreStrategic or Co-development PartnerLong-standing clinical research partnership with Assistance Publique - Hôpitaux de Paris at La Pitié-Salpêtrière hospital for respiratory function characterization studies and clinical validation.
  • CHU de BordeauxcoreStrategic or Co-development PartnerClinical collaboration with Centre Hospitalier Universitaire de Bordeaux for respiratory signal analysis research and clinical validation.
  • CHU de GrenoblecoreStrategic or Co-development PartnerClinical research partnership with Centre Hospitalier Universitaire de Grenoble for respiratory function studies.
  • CHU de LyoncoreStrategic or Co-development PartnerClinical collaboration with Centre Hospitalier Universitaire de Lyon for respiratory signal analysis research.
  • CHU de RouencoreStrategic or Co-development PartnerHospital partnership with Centre Hospitalier Universitaire de Rouen for clinical research collaboration.
  • Université Paris-SorbonnecoreStrategic or Co-development PartnerAcademic partnership with Sorbonne University for collaborative respiratory function research alongside APHP clinicians.
  • Université de BordeauxcoreStrategic or Co-development PartnerAcademic collaboration with University of Bordeaux Hospital for clinical research in respiratory medicine.
  • Université Grenoble-AlpescoreStrategic or Co-development PartnerAcademic partnership with Université Grenoble-Alpes (formerly Grenoble-Alphes) for respiratory research collaboration.
  • Allis-NA Alliance Innovation SantéminorGTM or Marketing PartnerAlliance Innovation Santé member organization focused on health innovation in Nouvelle-Aquitaine region.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Aqsitania competitors and assessment

Company assessment

Direct peers

  • TidalSense: TidalSense is a UK respiratory diagnostics and telehealth company using novel sensor and signal-analysis approaches (e.g., N-Tidal capnography) to diagnose and monitor chronic respiratory conditions — directly comparable in mission, technology approach, and clinical customer base to Aqsitania.
  • NuvoAir: NuvoAir is a digital-health company offering remote respiratory monitoring, virtual pulmonary care, and connected spirometry for patients with asthma, COPD, and cystic fibrosis — directly mirroring Aqsitania's chronic-respiratory telemonitoring use cases and target customers (patients, providers, payers).
  • Propeller Health (ResMed): Propeller Health (acquired by ResMed) provides connected inhaler sensors and digital respiratory health programs for asthma and COPD — a direct functional parallel to Aqsitania's Telesurveillance service for the same patient populations.
  • Adherium: Adherium designs connected inhaler sensors and remote respiratory monitoring platforms for asthma and COPD adherence, overlapping directly with Aqsitania's AMASR-based chronic-respiratory telemonitoring offering and target user base.
  • ResApp Health (acquired by Pfizer): ResApp developed smartphone-based respiratory-diagnostic algorithms (e.g., cough/sound analysis) for conditions such as COPD, asthma, and pneumonia — directly comparable to Aqsitania's software-based, non-effort-dependent respiratory assessment approach.

Broad incumbents

  • ResMed: ResMed is a global leader in connected sleep and respiratory care devices (CPAP, ventilation) and now owns Propeller Health; it competes in the same chronic-respiratory monitoring category as Aqsitania but operates at vastly greater scale and with established payer/provider integration.
  • Philips Respiratory Care: Philips is a major incumbent in hospital and home respiratory monitoring, ventilation, and telehealth; it competes broadly with Aqsitania across both hospital diagnostics (spirometry/ventilometry) and home telemonitoring, though not as a focused deep-tech niche player.

Emerging players

  • Bodyport: Bodyport builds a connected cardiovascular-monitoring scale that captures cardiac and respiratory signals for heart-failure and chronic-disease management, partially overlapping with Aqsitania's cardiac and cardio-respiratory signal-analysis service line.
  • VitalConnect: VitalConnect provides wearable biosensor patches and remote patient monitoring for cardiac and respiratory vital signs, an emerging-player analog to Aqsitania's connected-device-plus-software respiratory telemonitoring stack.
  • Spire Health: Spire Health offers wearable continuous respiratory and sleep monitoring for chronic-condition management, overlapping with Aqsitania's home-based telemonitoring and chronic-respiratory signal-analysis capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Aqsitania social profiles

Digital presence

Aqsitania financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aqsitania leadership team

Management profile

Number of profiles

Profiles1 record

Aqsitania funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aqsitania M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aqsitania

What does Aqsitania do?

Aqsitania provides respiratory telemonitoring and diagnostics for chronically ill patients (asthma, COPD/BPCO, cystic fibrosis, lung transplants) and professional athletes, powered by its proprietary AMASR signal processing technology. The company's core products include Ventilométrie (effort-free respiratory function assessment), the Personal Respiratory Profile (PRP), home-based telemonitoring services, the Ventilosmart consumer mobile application, and bespoke signal analysis projects. The technology enables new biomarkers and early detection of respiratory deterioration that traditional signal processing methods cannot identify.

Is Aqsitania a public or private company?

Aqsitania is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Aqsitania founded?

Aqsitania was founded in 2014. It employs 1 to 10 people.

Where is Aqsitania based?

Aqsitania is headquartered in Pessac, France, in the Europe region.

How does Aqsitania make money?

Four revenue lines are on record. Telemonitoring/Telesurveillance Services are the primary driver. The others are custom Signal Analysis Projects, sports Respiratory Evaluation and signal Analysis Service.

Who are Aqsitania's main competitors?

Direct peers on record are TidalSense, NuvoAir, Propeller Health (ResMed), Adherium and ResApp Health (acquired by Pfizer). Broad incumbents are ResMed and Philips Respiratory Care. Emerging players are Bodyport, VitalConnect and Spire Health.

Does Aqsitania have an API?

No public API is recorded for Aqsitania.

What industry is Aqsitania in?

Aqsitania's product category is Remote Patient Monitoring. Its primary akta.pro industry code is HLALAGAF, Pulmonology & Sleep Medicine Telemedicine Platforms, with a secondary code of HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate). Its NAICS code is 62151 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales